XLO - Xilio PEG Multiple

Brandmark of Xilio (XLO)

Xilio Therapeutics, Inc. (XLO) is developing its business based on tumor-specific cytokines, aiming to bring safe immuno-oncology agents to market. A strategic partnership with Gilead in lung cancer therapy strengthens the ecosystem under FDA oversight. The valuation-to-growth balance indicator demonstrates the asset's dynamics, where 0.00 reflects the latest metric value. The localization of molecule activation within tumors minimizes toxicity, enabling access to the treatment of advanced stages.

XLO: Xilio Therapeutics, Inc. PEG Multiple 07/04/2022 - 11/15/2026

Analytical breakdowns for Xilio (XLO)

- market price and analyst price targets:
Fundamental company analysis:Xilio XLO
Manufactured products of Xilio Therapeutics Inc

Investors use this criterion to identify undervalued assets with high expansion potential. The metric compares the P/E ratio to earnings growth rates, where a value below one signals undervaluation. For Xilio Therapeutics, Inc. (XLO), such calculations are critical, as the costs of complex cold-chain logistics directly impact margins. Analyzing the P/E-to-growth multiple allows for an assessment of the efficiency of these investments. This chart reflects market expectations regarding the pace of business development.

Competing companies

Price/Earnings to Growth Multiple BeiGene Ltd ONC|PEG Multiple HALO (halozyme.com)|RVMD - Price/Earnings to Growth Multiple|AAPG: Price/Earnings to Growth Multiple|CGON - PEG Multiple|UroGen (URGN) - Price/Earnings to Growth Ratio|Bicara Bio - Growth-Adjusted Payback Ratio|PSNL (Personalis Inc) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Erasca, Inc. ERAS|PEG Multiple DCTH|YMAB - Price to Earnings Adjusted for Growth Rate|Aura Biosciences Inc - Price/Earnings to Growth Multiple|PEG Multiple Candel Therapeutics CADL|accuray.com - PEG Multiple|SLS: Price/Earnings to Growth Ratio|ACTU (actuatetherapeutics.com) - Price/Earnings to Growth Multiple|CTOR - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio tuhurabio.com|PEG Multiple Protara Tx|Price/Earnings to Growth Multiple FATE (Fate Therapeutics Corp)|Price/Earnings to Growth Ratio WHWK (Aadi Bioscience)|TScan Therapeutics, Inc. - Price/Earnings to Growth Multiple|Champions Oncology (CSBR) - Price to Earnings Adjusted for Growth Rate|XBiotech - PEG Multiple|CEL-SCI (CVM) - Price/Earnings to Growth Multiple|OS Therapies Inc (OSTX) - Price/Earnings to Growth Ratio|radiopharmtheranostics.com - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Artiva Biotherapeutics Inc.|Price to Earnings Adjusted for Growth Rate Adlai Nortye Ltd. ANL|PEG Multiple VERU|TPST - Price to Earnings Adjusted for Growth Rate|PEG Multiple RENB (Renovaro Inc.)|Mural Bio (MURA) - Price to Earnings Adjusted for Growth Rate|Kairos Pharma Ltd - PEG Multiple|Market Cap to Earnings and Growth Ratio OKUR|CytoMed Therapeutics Limited (GDTC) - Price/Earnings to Growth Ratio|CRIS - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple APLM|Tharimmune (THAR) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple ADVB (Advanced Biomed Inc.)|Genprex - Growth-Adjusted P/E Ratio|PEG Multiple CLDI (Calidi Biotherapeutics, Inc.)|SBFM - Price/Earnings to Growth Multiple|Xenetic Bio - PEG Multiple|SLRX - PEG Multiple|PPBT: PEG Multiple|Growth-Adjusted P/E Ratio AONC|BGNE (BeiGene Ltd) - PEG Multiple|CKPT (Checkpoint Therapeutics, Inc) - Company Value to Earnings Growth Ratio|PEG Multiple ELEV|Price/Earnings to Growth Multiple iCAD Corp ICAD|Price/Earnings to Growth Ratio ikenaoncology.com IKNA|NTBL - Price/Earnings to Growth Multiple|VIRX - Price/Earnings to Growth Ratio|MOR - PEG Multiple|NAYA: PEG Multiple|Ascentage Pharma Group (AAPGV) - PEG Multiple